8 results on '"Currier, Judith S"'
Search Results
2. Experiences with telemedicine for HIV care in two federally qualified health centers in Los Angeles: a qualitative study
- Author
-
Walker, Daisy, Moucheraud, Corrina, Butler, Derrick, de Vente, Jerome, Tangonan, Kevin, Shoptaw, Steven, Currier, Judith S., Gladstein, Jay, and Hoffman, Risa
- Published
- 2023
- Full Text
- View/download PDF
3. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study.
- Author
-
Diaz, Chanelle M., Segura, Eddy R., Luz, Paula M., Clark, Jesse L., Ribeiro, Sayonara R., De Boni, Raquel, Eksterman, Leonardo, Moreira, Rodrigo, Currier, Judith S., Veloso, Valdiléa G., Grinsztejn, Beatriz, and Lake, Jordan E.
- Subjects
HIV infection risk factors ,CARDIOVASCULAR diseases ,TENOFOVIR ,AZIDOTHYMIDINE ,EFAVIRENZ ,RITONAVIR ,ATAZANAVIR ,CARDIOVASCULAR disease related mortality ,ANTI-HIV agents ,HYPERTENSION epidemiology ,HIV infection epidemiology ,AGE distribution ,BLACK people ,ETHNIC groups ,HIV ,HIV infections ,LONGITUDINAL method ,MULTIVARIATE analysis ,REGRESSION analysis ,RESEARCH funding ,RNA ,SEX distribution ,TIME ,WHITE people ,VIRAL load ,DISEASE incidence ,RETROSPECTIVE studies ,CD4 lymphocyte count - Abstract
Background: Antiretroviral therapy (ART) agents potentially associated with adverse metabolic profiles are commonly used in low- and middle-income countries. We assessed risk factors for cardiovascular disease (CVD)-related morbidity and mortality in a cohort of HIV-infected, ART-treated adults in Rio de Janeiro, Brazil.Methods: Hospital records and mortality data between 2000-2010 were examined for incident CVD-related ICD-10 and Coding of Death in HIV diagnoses among adults ≥18 years old on ART, enrolled in an observational cohort. Poisson regression models assessed associations between demographic and clinical characteristics and ART agent or class on CVD event risk.Results: Of 2960 eligible persons, 109 had a CVD event (89 hospitalizations, 20 deaths). Participants were 65 % male, 54 % white, and had median age of 37 and 4.6 years on ART. The median nadir CD4(+) T lymphocyte count was 149 cells/mm(3). The virologic suppression rate at the end of study follow-up was 60 %. In multivariable models, detectable HIV-1 RNA prior to the event, prior CVD, less time on ART, age ≥40 at study baseline, nadir CD4(+) T lymphocyte count ≤50 cells/mm(3), non-white race, male gender, and a history of hypertension were significantly associated with CVD event incidence (p < 0.05), in order of decreasing strength. In multivariate models, cumulative use of tenofovir, zidovudine, efavirenz and ritonavir-boosted atazanavir, darunavir and/or lopinavir were associated with decreased CVD event risk. Recent tenofovir and boosted atazanavir use were associated with decreased risk, while recent stavudine, nevirapine and unboosted nelfinavir and/or indinavir use were associated with increased CVD event risk.Conclusions: Virologic suppression and preservation of CD4(+) T-lymphocyte counts were as important as traditional CVD risk factor burden in determining incident CVD event risk, emphasizing the overall benefit of ART on CVD risk and the need for metabolically-neutral first- and second-line ART in resource-limited settings. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Supporting Treatment Adherence Readiness through Training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial.
- Author
-
Wagner, Glenn J., Linnemayr, Sebastien, Ghosh-Dastidar, Bonnie, Currier, Judith S., Hoffman, Risa, and Schneider, Stefan
- Subjects
HIV-positive persons ,THERAPEUTICS ,HIV infections ,ANTIRETROVIRAL agents ,PATIENT compliance ,BEHAVIOR modification ,RANDOMIZED controlled trials ,COUNSELING ,DIAGNOSIS of HIV infections ,HIV infections & psychology ,PATIENT education ,COMPARATIVE studies ,COST effectiveness ,DRUGS ,DRUG administration ,EXPERIMENTAL design ,HEALTH attitudes ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,RESEARCH protocols ,MOTIVATION (Psychology) ,RESEARCH ,RESEARCH funding ,TIME ,VIRAL load ,SOCIAL support ,EVALUATION research ,TREATMENT effectiveness ,ANTI-HIV agents ,ECONOMICS - Abstract
Background: Few HIV antiretroviral adherence interventions target patients before they start treatment, assess adherence readiness to determine the timing of treatment initiation, or tailor the amount of adherence support. The Supporting Treatment Adherence Readiness through Training (START) intervention, based on the information-motivation-behavioral skills model of behavior change, is designed to address these gaps with the inclusion of (1) brief pill-taking practice trials for enhancing pretreatment adherence counseling and providing a behavioral criterion for determining adherence readiness and the timing of treatment initiation and (2) a performance-driven dose regulation mechanism to tailor the amount of counseling to the individual needs of the patient and conserve resources. The primary aim of this randomized controlled trial is to examine the effects of START on antiretroviral adherence and HIV virologic suppression.Methods/design: A sample of 240 patients will be randomized to receive START or usual care at one of two HIV clinics. Primary outcomes will be optimal dose-taking adherence (>85 % prescribed doses taken), as measured with electronic monitoring caps, and undetectable HIV viral load. Secondary outcomes will include dose-timing adherence (>85 % prescribed doses taken on time) and CD4 count. Primary endpoints will be month 6 (short-term effect) and month 24 (to test durability of effect), though electronic monitoring will be continuous and a fully battery of assessments will be administered every 6 months for 24 months.Discussion: If efficacious and cost-effective, START will provide clinicians with a model for assessing patient adherence readiness and helping patients to achieve and sustain readiness and optimal treatment benefits.Trial Registration: ClinicalTrials.gov identifier NCT02329782 . Registered on 22 December 2014. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
5. Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.
- Author
-
Coelho, Lara, Cardoso, Sandra W., Luz, Paula M., Hoffman, Risa M., Mendonça, Laura, Veloso, Valdilea G., Currier, Judith S., Grinsztejn, Beatriz, and Lake, Jordan E.
- Subjects
HIV-positive persons ,VITAMIN D ,DIETARY supplements ,ANTIRETROVIRAL agents ,VITAMIN D deficiency - Abstract
Background: HIV infection and antiretroviral therapy (ART) may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART. We prospectively compared demographic and clinical parameters between vitamin D sufficient and insufficient HIV-infected (HIV+) adults, and assessed changes in these parameters among insufficient participants following standardized vitamin D supplementation. Methods: HIV+ adults (≥18 years old) with HIV-1 RNA <50 copies/mL on ART were enrolled. Vitamin D sufficiency and insufficiency were defined as 25-hydroxyvitamin D (25(OH)D) ≥30 or <30 ng/mL, respectively. Insufficient participants received open-label vitamin D3 50,000 IU twice weekly for 5 weeks, then 8000 IU twice weekly to complete 24 weeks. The primary endpoint was success or failure to achieve 25(OH)D ≥30 ng/mL at week 24. Results: Ninety-seven participants enrolled (34 vitamin D sufficient, 63 insufficient); 32 % female, 47 % non-White, median age 46 years, ART duration 5 years, CD4+ T lymphocyte count (CD4) 673 cells/mm³. 25(OH)D repletion was 83 % (95 % CI 71 %-90 %) successful. 25(OH)D levels correlated with both CD4 (r = 0.44, p = 0.01) and time on protease inhibitor (r = -0.35, p = 0.01). After adjusting for age, sex, race, nadir CD4 and baseline 25(OH)D: 1) current use of efavirenz exposure was associated with a 21.1 ng/mL higher week 24 25(OH)D level (p = 0.007), 2) per year use of zidovudine was associated with 7.1 ng/mL reduction in week 24 serum 25(OH)D (p = 0.05) and 3) every 1 ng/mL 25(OH)D increase was associated with a 3.3 cell/mm³ CD4 increase (p = 0.06). Conclusion: Vitamin D
3 supplementation was effective in repleting 25(OH)D levels after 24 weeks. Current efavirenz use was positively associated with post-repletion 25(OH)D levels, while greater time on zidovudine was associated with lower post-repletion 25(OH)D levels. The association between improved CD4 recovery and vitamin D repletion suggests a potential benefit of vitamin D supplementation on immunologic recovery during HIV treatment. Trial registration: This trial is registered at The Brazilian Clinical Trials Registry (U1111-1165-2537). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
6. Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults.
- Author
-
Kelesidis, Theodoros, Yang, Otto O., Kendall, Michelle A., Hodis, Howard N., and Currier, Judith S.
- Subjects
ATHEROSCLEROSIS risk factors ,HIGH density lipoproteins ,HIV infections ,OXIDATION-reduction reaction ,CAROTID artery ,PROTEASE inhibitors ,PHENOTYPES - Abstract
Background: HDL function rather than absolute level may be a more accurate indicator for risk of developing atherosclerosis. Dysfunctional HDL has increased redox activity and reduced antioxidant properties, but it is unknown whether abnormal HDL function is associated with progression of atherosclerosis in HIV-1-infected subjects. Findings: We retrospectively measured serum HDL function in 91 subjects from a prospective 3-year study of carotid artery intima-media thickness (CIMT), which enrolled triads of risk factor-matched persons that were HIV-1-uninfected (n=36) or HIV-1+ with (n=29) or without (n=26) protease inhibitor (PI)-based therapy for = 2 years. HDL function was assessed using a biochemical assay that measures the oxidation of dihydrorhodamine 123 (DHR oxidation rate, DOR), in which higher DOR readout corresponds to dysfunctional HDL phenotype. There were no significant associations between DOR and HIV-1 infection. In univariate analysis of 55 HIV-1-infected subjects, greater waist circumference and lower serum HDL were significantly associated with higher baseline levels of DOR (p=0.01). These subjects had significant increases in levels of DOR over time (3 years) that were associated with white race (p=0.03), higher nadir CD4 count (p<0.001), and lower baseline CIMT (p<0.001). Lower baseline HDL levels, but not function of HDL (p>0.1) (DOR), were significantly associated (p=0.02) with progression of CIMT. Conclusion: In a small matched cohort study of HIV-1-infected subjects who had a low cardiovascular risk profile, HDL function changed over time and was independently associated with anthropometric parameters of obesity but not with progression of CIMT [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.
- Author
-
Kelesidis, Theodoros, Yang, Otto O., Currier, Judith S., Navab, Kaveh, Fogelman, Alan M., and Navab, Mohamad
- Subjects
HIV-positive persons ,HIV infections ,ANTIVIRAL agents ,BLOOD plasma ,VIREMIA - Abstract
Background: The role of pro-inflammatory lipids in systemic immune activation in HIV infection remains largely unknown. We hypothesized that HIV-1-infected persons on antiretroviral therapy would have pro-inflammatory high density lipoprotein (HDL), and that an apoA-1 mimetic peptide might reverse the inflammatory properties of HDL in these persons. Methods: Plasma was obtained from 10 HIV-1-infected individuals on combination antiretroviral therapy with suppressed viremia and was incubated with the apoA-I mimetic peptide L-4F or sham-treated prior to isolation of HDL. The HDL that was isolated from each sample was tested for its ability to inhibit LDL-induced MCP-1 production in cultures of human aortic endothelial cells. Results: We found in a small pilot study of HIV-1-infected individuals with suppressed viremia on combination antiretroviral therapy that oxidative stress and inflammation in HIV-1 are associated with a marked reduction of HDL antioxidant/anti-inflammatory activities. In vitro, these abnormalities were significantly improved by treatment with the apoA-1 mimetic peptide, 4F. Conclusions: These preliminary observations suggest that the anti-inflammatory properties of HDL are defective in HIV-1-infected persons despite treatment that is considered to be virologically successful. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.
- Author
-
Coelho, Lara, Cardoso, Sandra W, Luz, Paula M, Hoffman, Risa M, Mendonça, Laura, Veloso, Valdilea G, Currier, Judith S, Grinsztejn, Beatriz, and Lake, Jordan E
- Abstract
Background: HIV infection and antiretroviral therapy (ART) may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART. We prospectively compared demographic and clinical parameters between vitamin D sufficient and insufficient HIV-infected (HIV+) adults, and assessed changes in these parameters among insufficient participants following standardized vitamin D supplementation.Methods: HIV+ adults (≥ 18 years old) with HIV-1 RNA <50 copies/mL on ART were enrolled. Vitamin D sufficiency and insufficiency were defined as 25-hydroxyvitamin D (25(OH)D) ≥ 30 or <30 ng/mL, respectively. Insufficient participants received open-label vitamin D3 50,000 IU twice weekly for 5 weeks, then 8000 IU twice weekly to complete 24 weeks. The primary endpoint was success or failure to achieve 25(OH)D ≥ 30 ng/mL at week 24.Results: Ninety-seven participants enrolled (34 vitamin D sufficient, 63 insufficient); 32% female, 47% non-White, median age 46 years, ART duration 5 years, CD4+ T lymphocyte count (CD4) 673 cells/mm(3). 25(OH)D repletion was 83% (95% CI 71%-90%) successful. 25(OH)D levels correlated with both CD4 (r = 0.44, p = 0.01) and time on protease inhibitor (r = -0.35, p = 0.01). After adjusting for age, sex, race, nadir CD4 and baseline 25(OH)D: 1) current use of efavirenz exposure was associated with a 21.1 ng/mL higher week 24 25(OH)D level (p = 0.007), 2) per year use of zidovudine was associated with 7.1 ng/mL reduction in week 24 serum 25(OH)D (p = 0.05) and 3) every 1 ng/mL 25(OH)D increase was associated with a 3.3 cell/mm(3) CD4 increase (p = 0.06).Conclusion: Vitamin D3 supplementation was effective in repleting 25(OH)D levels after 24 weeks. Current efavirenz use was positively associated with post-repletion 25(OH)D levels, while greater time on zidovudine was associated with lower post-repletion 25(OH)D levels. The association between improved CD4 recovery and vitamin D repletion suggests a potential benefit of vitamin D supplementation on immunologic recovery during HIV treatment.Trial Registration: This trial is registered at The Brazilian Clinical Trials Registry (U1111-1165-2537). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.